Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients

R. Schandalik, G. Gatti, E. Perucca

Research output: Contribution to journalArticle

Abstract

The biliary excretion of silybin, the main active component of silymarin, was evaluated by using a specific HPLC method in 9 cholecystectomy patients with T-tube drainage following single oral doses of silipide (CAS 134499-06-2), a lipophilic silybin-phosphatidylcholine complex (IdB 1016), and of silymarin (120 mg, expressed as silybin equivalents). After intake of silipide, the concentration of silybin in bile reached a peak within 4 h and declined thereafter with a mean time of about 10 h. After administration of silymarin, biliary silybin concentrations were several-fold lower than those observed after intake of silipide. The bile collected after silymarin-intake also contained considerable amounts of isosilybin (a silybin isomer) and very low levels of silydianin and silycristin. The amount of silybin recovered in bile in free and conjugated form within 48 h accounted for 11% of the dose after silipide and for 3% of the dose after silymarin. Plasma silybin concentrations, determined in 3 subjects, were several-fold lower than those in bile after intake of silipide and mostly undetectable after intake of silymarin. These data indicate that the bioavailability of silybin is much greater after administration of silipide than after administration of silymarin. This results in increased delivery of the compound to the liver, which represents the target organ for pharmacological action.

Original languageEnglish
Pages (from-to)964-968
Number of pages5
JournalArzneimittel-Forschung/Drug Research
Volume42
Issue number7
Publication statusPublished - 1992

Fingerprint

IdB 1016
Silymarin
Pharmacokinetics
Cholecystectomy
Bile
silybin

Keywords

  • CAS 134499-06-2
  • IdB 1016
  • liver therapeutics
  • silipide, clinical pharmacokinetics
  • silybin
  • silymarin

ASJC Scopus subject areas

  • Chemistry(all)
  • Organic Chemistry
  • Drug Discovery
  • Pharmacology

Cite this

Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. / Schandalik, R.; Gatti, G.; Perucca, E.

In: Arzneimittel-Forschung/Drug Research, Vol. 42, No. 7, 1992, p. 964-968.

Research output: Contribution to journalArticle

@article{4ece85e1c7e94308a4a60e035b4a9ac2,
title = "Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients",
abstract = "The biliary excretion of silybin, the main active component of silymarin, was evaluated by using a specific HPLC method in 9 cholecystectomy patients with T-tube drainage following single oral doses of silipide (CAS 134499-06-2), a lipophilic silybin-phosphatidylcholine complex (IdB 1016), and of silymarin (120 mg, expressed as silybin equivalents). After intake of silipide, the concentration of silybin in bile reached a peak within 4 h and declined thereafter with a mean time of about 10 h. After administration of silymarin, biliary silybin concentrations were several-fold lower than those observed after intake of silipide. The bile collected after silymarin-intake also contained considerable amounts of isosilybin (a silybin isomer) and very low levels of silydianin and silycristin. The amount of silybin recovered in bile in free and conjugated form within 48 h accounted for 11{\%} of the dose after silipide and for 3{\%} of the dose after silymarin. Plasma silybin concentrations, determined in 3 subjects, were several-fold lower than those in bile after intake of silipide and mostly undetectable after intake of silymarin. These data indicate that the bioavailability of silybin is much greater after administration of silipide than after administration of silymarin. This results in increased delivery of the compound to the liver, which represents the target organ for pharmacological action.",
keywords = "CAS 134499-06-2, IdB 1016, liver therapeutics, silipide, clinical pharmacokinetics, silybin, silymarin",
author = "R. Schandalik and G. Gatti and E. Perucca",
year = "1992",
language = "English",
volume = "42",
pages = "964--968",
journal = "Arzneimittel-Forschung/Drug Research",
issn = "0004-4172",
publisher = "Editio Cantor Verlag GmbH",
number = "7",

}

TY - JOUR

T1 - Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients

AU - Schandalik, R.

AU - Gatti, G.

AU - Perucca, E.

PY - 1992

Y1 - 1992

N2 - The biliary excretion of silybin, the main active component of silymarin, was evaluated by using a specific HPLC method in 9 cholecystectomy patients with T-tube drainage following single oral doses of silipide (CAS 134499-06-2), a lipophilic silybin-phosphatidylcholine complex (IdB 1016), and of silymarin (120 mg, expressed as silybin equivalents). After intake of silipide, the concentration of silybin in bile reached a peak within 4 h and declined thereafter with a mean time of about 10 h. After administration of silymarin, biliary silybin concentrations were several-fold lower than those observed after intake of silipide. The bile collected after silymarin-intake also contained considerable amounts of isosilybin (a silybin isomer) and very low levels of silydianin and silycristin. The amount of silybin recovered in bile in free and conjugated form within 48 h accounted for 11% of the dose after silipide and for 3% of the dose after silymarin. Plasma silybin concentrations, determined in 3 subjects, were several-fold lower than those in bile after intake of silipide and mostly undetectable after intake of silymarin. These data indicate that the bioavailability of silybin is much greater after administration of silipide than after administration of silymarin. This results in increased delivery of the compound to the liver, which represents the target organ for pharmacological action.

AB - The biliary excretion of silybin, the main active component of silymarin, was evaluated by using a specific HPLC method in 9 cholecystectomy patients with T-tube drainage following single oral doses of silipide (CAS 134499-06-2), a lipophilic silybin-phosphatidylcholine complex (IdB 1016), and of silymarin (120 mg, expressed as silybin equivalents). After intake of silipide, the concentration of silybin in bile reached a peak within 4 h and declined thereafter with a mean time of about 10 h. After administration of silymarin, biliary silybin concentrations were several-fold lower than those observed after intake of silipide. The bile collected after silymarin-intake also contained considerable amounts of isosilybin (a silybin isomer) and very low levels of silydianin and silycristin. The amount of silybin recovered in bile in free and conjugated form within 48 h accounted for 11% of the dose after silipide and for 3% of the dose after silymarin. Plasma silybin concentrations, determined in 3 subjects, were several-fold lower than those in bile after intake of silipide and mostly undetectable after intake of silymarin. These data indicate that the bioavailability of silybin is much greater after administration of silipide than after administration of silymarin. This results in increased delivery of the compound to the liver, which represents the target organ for pharmacological action.

KW - CAS 134499-06-2

KW - IdB 1016

KW - liver therapeutics

KW - silipide, clinical pharmacokinetics

KW - silybin

KW - silymarin

UR - http://www.scopus.com/inward/record.url?scp=0026776782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026776782&partnerID=8YFLogxK

M3 - Article

C2 - 1329780

AN - SCOPUS:0026776782

VL - 42

SP - 964

EP - 968

JO - Arzneimittel-Forschung/Drug Research

JF - Arzneimittel-Forschung/Drug Research

SN - 0004-4172

IS - 7

ER -